Friday, September 05, 2014 9:38:38 AM
That's a pretty succinct and accurate summary of the problem that NNVC faces here tryn2makamil. Same with anybody else developing a drug or treatment for Ebola/Marburg - There really is no good way to test it's effectiveness in people - without testing it in people.
And since the people who need the drugs / treatments are not particularly conveniently located, and the countries that they are in have infrastructure issues - that's an added bit of challenge.
And - although some of the potential ethical snags may be been suspended after WHO's bioethics statements of last month - some really basic safety testing (that 'first do no harm' bit) would still seem in order before an Ebolacide II would be pressed into service.
Hopefully - NNVC and the Drs. are getting this all rolling with their old USAMRIID collaborators at Ft. Detrick and this can be addressed in reasonably short order.
IF the Drs. can work the bugs out of the ligands so that they generally do not bind to the decoys that the Ebola virus produces AND more specifically target the real receptor - chances are the 'Cide is safe enough to deploy, and just might be effective if you can get it to infected people before major tissue damage has accumulated.
And since the people who need the drugs / treatments are not particularly conveniently located, and the countries that they are in have infrastructure issues - that's an added bit of challenge.
And - although some of the potential ethical snags may be been suspended after WHO's bioethics statements of last month - some really basic safety testing (that 'first do no harm' bit) would still seem in order before an Ebolacide II would be pressed into service.
Hopefully - NNVC and the Drs. are getting this all rolling with their old USAMRIID collaborators at Ft. Detrick and this can be addressed in reasonably short order.
IF the Drs. can work the bugs out of the ligands so that they generally do not bind to the decoys that the Ebola virus produces AND more specifically target the real receptor - chances are the 'Cide is safe enough to deploy, and just might be effective if you can get it to infected people before major tissue damage has accumulated.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
